<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37058074</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>15</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>14</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Genotype and clinical phenotype analysis of a Family with Kennedy disease.</ArticleTitle><Pagination><StartPage>e33502</StartPage><MedlinePgn>e33502</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e33502</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000033502</ELocationID><Abstract><AbstractText>To investigate the clinical phenotype-genotype correlations of a family with Kennedy disease (KD) and improve our understanding of the disease. KD was confirmed after clinical phenotypic analyses, laboratory tests, polymerase chain reaction assays for cytosine-adenine-guanine (CAG) repeats, and neuro-electrophysiological tests. The disease was assessed using the KD1234 scale and the spinal and bulbar muscular atrophy functional rating scale. The average age of disease onset was 30.8&#x2009;&#xb1;&#x2009;2.85 years. Clinically diagnosed members had 48 CAG repeats (&#x2265;35 is abnormal) in the androgen receptor gene. The patients exhibited gynecomastia and testicular dysfunction. The lesions mainly involved the medulla oblongata and spinal cord. Progesterone and serum creatine kinase levels were significantly high. Electromyography showed chronic neurogenic damage and abnormal sensory and motor conduction in family members who did not participate in sports, exercise, or physical hobbies. Our study showed that this family had a stable inheritance of CAG repeats, and the genotype was consistent with the clinical phenotype. Gynecomastia was the first symptom, with progressive androgen resistance resulting in testicular atrophy, infertility, and sexual dysfunction. Changes in serum creatine kinase may indicate the progression or relief of symptoms, and rehabilitation may delay the progression of muscle atrophy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Ben-Chi</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Li-Fan</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan-Hui</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Sui</LastName><ForeName>Zhi-Yan</ForeName><Initials>ZY</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Dan-Ting</ForeName><Initials>DT</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xi</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wen-Di</ForeName><Initials>WD</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Tao</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3106-9628</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="Y">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006177" MajorTopicYN="Y">Gynecomastia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009133" MajorTopicYN="N">Muscular Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003402" MajorTopicYN="N">Creatine Kinase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>10</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37058074</ArticleId><ArticleId IdType="pmc">PMC10101244</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000033502</ArticleId><ArticleId IdType="pii">00005792-202304140-00064</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lu M, Guo H, Fan D. Kennedy&#x2019;s disease 1234 scale: preliminary design and test. J Clin Neurosci. 2017;40:185&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28242130</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, et al. . Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352:77&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgunder JM, Sch&#xf6;ls L, Baets J, et al. . EFNS guidelines for the molecular diagnosis of neurogenetic disorders: motoneuron, peripheral nerve and muscle disorders. Eur J Neurol. 2011;18:207&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">20500522</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat PF, Bernard E, Corcia P, et al. . The French national protocol for Kennedy&#x2019;s disease (SBMA): consensus diagnostic and management recommendations. Orphanet J Rare Dis. 2020;15:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149864</ArticleId><ArticleId IdType="pubmed">32276665</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, et al. . A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study. Neuromuscul Disord. 2015;25:554&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5608513</ArticleId><ArticleId IdType="pubmed">25913211</ArticleId></ArticleIdList></Reference><Reference><Citation>Breza M, Koutsis G. Kennedy&#x2019;s disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease. J Neurol. 2019;266:565&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">30006721</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi V, Querin G, Ziff OJ, et al. . Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology. 2019;92:e1205&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511101</ArticleId><ArticleId IdType="pubmed">30787165</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Rhodes LE, Kokkinis AD, White MJ, et al. . Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011;10:140&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056353</ArticleId><ArticleId IdType="pubmed">21216197</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirunagi T, Sahashi K, Meilleur KG, et al. . Nucleic acid-based therapeutic approach for spinal and bulbar muscular atrophy and related neurological disorders. Genes (Basel). 2022;13:109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8775157</ArticleId><ArticleId IdType="pubmed">35052449</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Rojas VA, Jimenez-Garduno AM, Michelatti D, et al. . ClC-2-like chloride current alterations in a cell model of spinal and bulbar muscular atrophy, a polyglutamine disease. J Mol Neurosci. 2021;71:662&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">32856205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Fischbeck KH, Pennuto M, et al. . Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA). J Neurol Neurosurg Psychiatry. 2020;91:1085&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">32934110</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, Bertolin C, Da Re E, et al. . Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. J Neurol Neurosurg Psychiatry. 2016;87:810&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4975824</ArticleId><ArticleId IdType="pubmed">26503015</ArticleId></ArticleIdList></Reference><Reference><Citation>Heje K, Andersen G, Buch A, et al. . High-intensity training in patients with spinal and bulbar muscular atrophy. J Neurol. 2019;266:1693&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31004213</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotkine M, Friedlander Y, Hochner H. Triathletes are over-represented in a population of patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:534&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25007701</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A, Hirsch S, Volk AE, et al. . The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy. J Neurol. 2018;265:1026&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">29464380</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Chen Q, Li Q, et al. . [Clinical features of a genetically identified spinal and bulbar muscular atrophy pedigree]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016;41:1101&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27807335</ArticleId></ArticleIdList></Reference><Reference><Citation>Soukup GR, Sperfeld AD, Uttner I, et al. . Frontotemporal cognitive function in X-linked spinal and bulbar muscular atrophy (SBMA): a controlled neuropsychological study of 20 patients. J Neurol. 2009;256:1869&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">19572162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasper E, Wegrzyn M, Marx I, et al. . Minor cognitive disturbances in X-linked spinal and bulbar muscular atrophy, Kennedy&#x2019;s disease. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">24200287</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Rosa E, Sorar&#xf9; G, Kleinbub JR, et al. . Theory of mind, empathy and neuropsychological functioning in X-linked spinal and bulbar muscular atrophy: a controlled study of 20 patients. J Neurol. 2015;262:394&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">25408365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Lim YM, Lee EJ, et al. . Correlation between the CAG repeat size and electrophysiological findings in patients with spinal and bulbar muscular atrophy. Muscle Nerve. 2018;57:683&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">28972672</ArticleId></ArticleIdList></Reference><Reference><Citation>Hama T, Hirayama M, Hara T, et al. . Discrimination of spinal and bulbar muscular atrophy from amyotrophic lateral sclerosis using sensory nerve action potentials. Muscle Nerve. 2012;45:169&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">22246870</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>